For decades, the diagnosis of multiple myeloma required evidence of end-organ damage characterized by myeloma-defining events (MDEs) known as CRAB: Diagnosis also required -- and still does -- the ...

Shares of bioAffinity Technologies, Inc. BIAF have surged 160.9% since the company reported its financial results for the year ended Dec. 31, 2024. In stark contrast, the S&P 500 Index declined 8.9% ...

According to Vantage Market Research, the Global Flow Cytometry Market is estimated to be valued at USD 14 Billion by 2035 at an exponential growth of 9.65% in the next seven years. The increasing ...

To support physicians in treating cancer patients, oncology laboratories can benefit from adopting end-to-end automation of flow cytometry workflows. Rapid advances in automation are improving ...

The end result is a fully integrated optofluidic platform in which the borosilicate glass chip contains reconfigurable ...

Ahead of AACR 2025, Charles River announces updates to its comprehensive portfolio to support the discovery and development of novel oncology drugs.

Flow Cytometry, and BLI for the validation of antibody binding to the target(s) of interest. “We’re confident that our antibody discovery platform can deliver high-quality inputs that will be ...

Kanazawa University, demonstrate a novel approach for nanoscopic profiling of small extracellular vesicles (sEVs) using ...

These assays are analyzed using flow cytometry and live cell imaging with IncuCyte. IncuCyte-based assays quantify the number of viable target cells and can be multiplexed with an apoptotic readout.